Trius Therapeutics Announces Exercise of Underwriters' Overallotment Option
Trius Therapeutics, Inc. (Nasdaq: TSRX) today announced that the underwriters of its previously announced public offering of common stock that priced on January 17, 2013, have exercised their option to purchase an additional 869,135 shares of common stock. With the sale of the additional shares, Trius will have sold a total of 7,169,135 shares of common stock in the public offering at a price to the public of $4.75 per share, resulting in expected aggregate gross proceeds to Trius of approximately $34.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trius. The offering, including the sale of the additional shares, is expected to close on or about January 24, 2013, subject to customary closing conditions.
Trius anticipates using the net proceeds from the offering for general corporate purposes, including clinical trial, preclinical and other research and development expenses, capital expenditures, working capital and general and administrative expenses.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.